Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib for non-segmental vitiligo in adults and adolescents
NL-OMON59954Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Vitiligo comparing Upadacitinib 15 mg with Placebo (2 arms). Primary endpoints: Achievement of T-VASI 50 at Week 48 and Achievement of F-VASI 75 at Week 48. Started May 2024; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NL-OMON59954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59954.